title: Mortality risk stratification in severely anaemic Jehovah's Witness patients.
abstract: The aim of this retrospective cohort study was to identify early risk factors of mortality and develop a mortality risk stratification instrument for severely anaemic Jehovah's Witness patients. It has been shown that Jehovah's Witness patients with the Auckland Anaemia Mortality Risk Score (Auckland AMRS) of 0 to 3 had 4% mortality, Auckland AMRS 4 to 5 32%, Auckland AMRS 6 to 7 50% and Auckland AMRS 8 and above 83%. It is concluded that the Auckland AMRS predicts mortality of severely anaemic Jehovah's Witness patients.
authors.affiliation: Department of General Surgery, Auckland City Hospital, Auckland, New Zealand. andreib@adhb.govt.nz
authors.forename: A M
authors.initials: AM
authors.lastname: Beliaev
authors.forename: R J
authors.initials: RJ
authors.lastname: Marshall
authors.forename: W
authors.initials: W
authors.lastname: Smith
authors.forename: J A
authors.initials: JA
authors.lastname: Windsor
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000188:drug therapy / Q000453:epidemiology*; D002318:Cardiovascular Diseases / Q000401:mortality; D004921:Erythropoietin / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D005260:Female; D000069585:Filgrastim; D005492:Folic Acid / Q000627:therapeutic use; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D006470:Hemorrhage / Q000401:mortality; D017052:Hospital Mortality; D006779:Hospitals, Public / Q000706:statistics & numerical data; D006801:Humans; D007239:Infections / Q000401:mortality; D007501:Iron / Q000627:therapeutic use; D033221:Jehovah's Witnesses; D007676:Kidney Failure, Chronic / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009520:New Zealand / Q000453:epidemiology; D010949:Plasma; D011183:Postoperative Complications / Q000401:mortality; D011994:Recombinant Proteins / Q000627:therapeutic use; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D014805:Vitamin B 12 / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D016179:Granulocyte Colony-Stimulating Factor; D005492:Folic Acid; C103587:recombinant FVIIa; D007501:Iron; D015942:Factor VIIa; D014805:Vitamin B 12; D000069585:Filgrastim